What Is Dihexa?
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) was developed at Washington State University by Joseph W. Harding and colleagues. It's a small, orally bioavailable peptidomimetic — meaning it mimics the function of a larger peptide but in a compact, stable form that can be taken systemically.
Its core mechanism centers on potentiation of the HGF/c-Met signaling axis, a pathway critical to neuronal survival, synaptic formation, and long-term potentiation (LTP). Early preclinical studies showed Dihexa to be approximately 10 million times more potent than brain-derived neurotrophic factor (BDNF) at promoting synaptogenesis in rodent models — a staggering benchmark that placed it at the frontier of cognitive neuroscience research.
Dihexa is currently investigational. It is not FDA-approved for any medical indication and all data referenced here derives from preclinical and early-stage research.
How Dihexa Works: Rebuilding Synaptic Architecture
Dihexa's therapeutic potential hinges on its ability to amplify hepatocyte growth factor (HGF) and its receptor c-Met — a signaling duo that governs some of the brain's most fundamental repair processes.
HGF/c-Met Potentiation
Dihexa binds HGF and enhances its binding affinity to c-Met receptors on neurons, dramatically amplifying downstream repair signaling without directly activating c-Met itself.
Synaptogenesis Activation
Downstream c-Met signaling triggers dendritic spine formation and axonal sprouting — physically rebuilding the synaptic connections lost to injury, disease, or aging.
Long-Term Potentiation
Enhanced synaptic density supports LTP — the cellular basis of memory consolidation — restoring cognitive function in models of neurodegeneration.
Neuronal Survival
c-Met activation promotes anti-apoptotic pathways, protecting existing neurons from programmed cell death during neuroinflammatory or ischemic insults.
Healthy Brain vs. Degenerating Brain
The contrast between a healthy neural environment and one afflicted by neurodegeneration is stark — and it's precisely this gap that Dihexa aims to close by restoring synaptic connectivity at the cellular level.
Healthy Brain
• Dense, richly interconnected dendritic spines
• Robust LTP and efficient neurotransmission
• Active HGF/c-Met signaling sustaining plasticity
• Neurons firing in synchronized, organized networks
Degenerating Brain
• Sparse, fragmented dendritic spines
• Impaired LTP and neurotransmitter dysregulation
• Reduced HGF/c-Met activity and neurotrophic support
• Progressive neuronal apoptosis and circuit collapse
Research Indications Under Investigation
Alzheimer's Disease
In rodent models of Alzheimer's, Dihexa reversed cognitive deficits and restored spatial memory. A patient with early-stage Alzheimer's enrolled in a compassionate-use protocol reportedly experienced measurable improvements in word recall and daily task orientation within weeks of transdermal administration.
Stroke & Ischemic Injury
Post-ischemic neurons face rapid apoptosis. Dihexa's c-Met activation promotes survival of penumbral tissue — the vulnerable zone surrounding a stroke core. Caregivers of post-stroke patients on experimental protocols have described accelerated rehabilitation milestones in speech and motor coordination.
Parkinson's Disease
While primarily a dopaminergic disease, Parkinson's involves widespread synaptic loss. Dihexa may slow this secondary neurodegeneration. Early anecdotal reports note improvements in non-motor symptoms — mental clarity, mood, reduced cognitive fog — alongside standard therapy.
PTSD & Cognitive Decline
Trauma rewires synaptic architecture in the prefrontal cortex and hippocampus. Dihexa's ability to promote new synapse formation may facilitate therapeutic reconsolidation. A veteran participant in an early trial reported improved emotional regulation and reduction in intrusive memory frequency after 8 weeks of low-dose therapy.
TBI & Contact Sports: A Growing Crisis
Traumatic brain injury (TBI) affects an estimated 1.7 million Americans annually, with contact-sport athletes — particularly football players — representing one of the most studied and at-risk populations. Repeated subconcussive impacts accelerate synaptic loss, neuroinflammation, and in chronic cases, the development of Chronic Traumatic Encephalopathy (CTE).
Dihexa's mechanism is directly relevant: by amplifying HGF-mediated repair signaling after acute mechanical injury, it may reduce the cascade of secondary neuronal death that accounts for a majority of long-term TBI disability. Preclinical rodent TBI models showed marked improvement in spatial navigation and reduced cortical lesion volume following Dihexa administration.
- 1.7M: Estimated U.S. annual TBI incidence
- 300K: Sport-related concussions in U.S. athletes per year
- 10M+: Times more potent than BDNF in synaptogenesis models
Dosing & Delivery Methods
Because Dihexa is investigational and not FDA-approved, dosing information is derived exclusively from preclinical studies, researcher communications, and anecdotal self-experimentation reports within the longevity research community. All usage is off-label and should only be pursued under qualified medical supervision.
Transdermal (Most Common)
Dissolved in DMSO or a transdermal cream. Typical reported range: 10–30 mg applied to inner wrist or forearm. Preferred for ease of use and relatively consistent absorption. Onset reported within 30–60 minutes. Frequency: 1–3× per week to avoid tachyphylaxis.
Oral (Capsule)
Orally bioavailable due to peptidomimetic structure. Reported doses: 10–25 mg in capsule form. Bioavailability may be lower than transdermal due to first-pass metabolism. Some protocols suggest sublingual administration for faster uptake.
Subcutaneous Injection
Used in research protocols at lower doses (1–10 mg) for more precise systemic delivery. Injection site: abdomen or upper arm. Not commonly used outside clinical research due to preparation requirements and sterility demands.
Intranasal
An emerging route leveraging direct olfactory-to-CNS transport. Bypasses blood-brain barrier entirely. Early reports suggest doses as low as 1–5 mg intranasally may be effective. Preparation requires pharmaceutical-grade saline suspension.
Cycling protocols (e.g., 2 weeks on / 2 weeks off) are commonly recommended in the research community to maintain receptor sensitivity and avoid downregulation of c-Met signaling over time.